NO3021859T3 - - Google Patents
Info
- Publication number
- NO3021859T3 NO3021859T3 NO14799117A NO14799117A NO3021859T3 NO 3021859 T3 NO3021859 T3 NO 3021859T3 NO 14799117 A NO14799117 A NO 14799117A NO 14799117 A NO14799117 A NO 14799117A NO 3021859 T3 NO3021859 T3 NO 3021859T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201318885A GB201318885D0 (en) | 2013-10-25 | 2013-10-25 | Adenovirus |
| GBGB1318880.0A GB201318880D0 (en) | 2013-10-25 | 2013-10-25 | Adenovirus |
| GBGB1322851.5A GB201322851D0 (en) | 2013-12-23 | 2013-12-23 | Method |
| GB201401159A GB201401159D0 (en) | 2014-01-23 | 2014-01-23 | Adenovirus |
| GB201406470A GB201406470D0 (en) | 2014-04-10 | 2014-04-10 | Virus |
| PCT/EP2014/072919 WO2015059303A1 (en) | 2013-10-25 | 2014-10-24 | Oncolytic adenoviruses armed with heterologous genes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3021859T3 true NO3021859T3 (enExample) | 2018-04-28 |
Family
ID=51900851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO14799117A NO3021859T3 (enExample) | 2013-10-25 | 2014-10-24 |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9987314B2 (enExample) |
| EP (3) | EP3372236A1 (enExample) |
| KR (1) | KR102272932B1 (enExample) |
| CN (2) | CN108064159B (enExample) |
| AU (1) | AU2014338864C1 (enExample) |
| CA (2) | CA2927968C (enExample) |
| CL (1) | CL2016000959A1 (enExample) |
| CY (1) | CY1119955T1 (enExample) |
| DK (1) | DK3021859T3 (enExample) |
| EA (1) | EA036414B1 (enExample) |
| ES (1) | ES2661132T3 (enExample) |
| HR (1) | HRP20180317T1 (enExample) |
| HU (1) | HUE035875T2 (enExample) |
| IL (2) | IL244944B (enExample) |
| LT (1) | LT3021859T (enExample) |
| MX (1) | MX373835B (enExample) |
| MY (1) | MY175614A (enExample) |
| NO (1) | NO3021859T3 (enExample) |
| NZ (1) | NZ718931A (enExample) |
| PE (1) | PE20160951A1 (enExample) |
| PH (1) | PH12016500759B1 (enExample) |
| PL (1) | PL3021859T3 (enExample) |
| PT (1) | PT3021859T (enExample) |
| RS (1) | RS57043B1 (enExample) |
| SA (1) | SA516371011B1 (enExample) |
| SG (2) | SG10201804030WA (enExample) |
| SI (1) | SI3021859T1 (enExample) |
| SM (1) | SMT201800130T1 (enExample) |
| TR (1) | TR201802728T4 (enExample) |
| WO (1) | WO2015059303A1 (enExample) |
| ZA (1) | ZA201603646B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015030881A2 (pt) | 2013-06-14 | 2017-10-24 | Psioxus Theraupeutics Ltd | regime de dosagem e formulações para adenovírus de tipo b |
| LT3021859T (lt) | 2013-10-25 | 2018-06-11 | Psioxus Therapeutics Limited | Onkolitiniai adenovirusai su heterologiniais genais |
| GB201406608D0 (en) * | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| GB201510197D0 (en) | 2014-06-12 | 2015-07-29 | Psioxus Therapeutics Ltd | Method of treating ovarian cancer |
| JP2017529070A (ja) | 2014-08-27 | 2017-10-05 | サイオクサス セラピューティクス リミテッド | アデノウイルスの製造方法 |
| WO2016134371A2 (en) | 2015-02-20 | 2016-08-25 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| HK1250918A1 (zh) | 2015-04-06 | 2019-01-18 | Cytoimmune Therapeutics, Inc. | 用於胶质母细胞瘤的egfr导向的car疗法 |
| HRP20200439T1 (hr) * | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| MY193281A (en) * | 2015-12-17 | 2022-09-30 | Psioxus Therapeutics Ltd | Group b adenovirus encoding an anti-tcr-complex antibody or fragment |
| CN109312309B (zh) | 2016-01-08 | 2024-04-02 | 雷普利穆内有限公司 | 工程化的病毒 |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| GB201713765D0 (en) * | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| KR102427563B1 (ko) * | 2016-08-29 | 2022-08-03 | 싸이오서스 테라퓨틱스 엘티디. | 이중특이성 T 세포 활성화제(Bispecific T cell activator)가 보강된 아데노바이러스 |
| WO2018083258A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083257A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083259A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| GB201700350D0 (en) * | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| WO2018170763A1 (zh) * | 2017-03-22 | 2018-09-27 | 深圳市博奥康生物科技有限公司 | ILA 基因的 RNAi 表达载体及其构建方法和应用 |
| TWI796329B (zh) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
| CN118308311A (zh) * | 2017-06-01 | 2024-07-09 | 阿卡米斯生物公司 | 溶瘤病毒和方法 |
| WO2019077113A1 (en) | 2017-10-20 | 2019-04-25 | F. Hoffmann-La Roche Ag | COPY PROTECTION FOR ANTIBODIES |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| WO2020010284A1 (en) * | 2018-07-04 | 2020-01-09 | Cytoimmune Therapeutics, LLC | Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1 |
| NZ771198A (en) | 2018-07-11 | 2024-11-29 | Actym Therapeutics Inc | Engineered immunostimulatory bacterial strains and uses thereof |
| JP2022502074A (ja) * | 2018-09-10 | 2022-01-11 | ジェネセイル バイオテック（シャンハイ）カンパニー リミテッド | 改変された腫瘍溶解性ウイルス、組成物、およびその使用 |
| JP2022521268A (ja) * | 2019-02-21 | 2022-04-06 | アンリーシュ イミュノ オンカリティクス，インコーポレイテッド | 腫瘍溶解性アデノウイルスベクター及び使用法 |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| MX2021010273A (es) | 2019-02-27 | 2021-09-23 | Actym Therapeutics Inc | Bacterias inmunoestimuladoras modificadas para colonizar tumores, celulas inmunitarias residentes de tumor y el microentorno tumoral. |
| GB201909081D0 (en) | 2019-06-25 | 2019-08-07 | Psioxus Therapeutics Ltd | Method |
| CA3161450A1 (en) | 2019-11-12 | 2021-05-20 | Actym Therapeutics, Inc. | Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products |
| KR20210118757A (ko) * | 2020-03-23 | 2021-10-01 | (주)큐리진 | STAT3 및 mTOR를 이중 특이적으로 표적하는 핵산서열을 포함한 항암 바이러스 |
| WO2021194181A1 (ko) * | 2020-03-23 | 2021-09-30 | ㈜큐리진 | Ar 및 mtor를 이중 특이적으로 표적하는 핵산분자를 포함하는 항암바이러스 |
| EP4148126A4 (en) * | 2020-03-25 | 2025-01-08 | Curigin Co.,Ltd. | ANTI-TUMOR ADENOVIRUS IMMUNO-EVASIVE |
| JP2023520402A (ja) * | 2020-03-31 | 2023-05-17 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | プロピオン酸血症を処置するための遺伝子治療 |
| JP2023539454A (ja) | 2020-08-12 | 2023-09-14 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム |
| CN114717203B (zh) * | 2020-12-22 | 2023-06-27 | 广东东阳光药业有限公司 | 一种hIL7/hCCL19双基因重组溶瘤病毒及其制备方法和用途 |
| US20240108752A1 (en) * | 2020-12-22 | 2024-04-04 | Ensoma, Inc. | Adenoviral gene therapy vectors |
| GB202102049D0 (en) | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
| US20240398939A1 (en) | 2021-09-23 | 2024-12-05 | Sagittarius Bio, Inc. | Adenoviruses and methods for using adenoviruses |
| EP4429682A2 (en) | 2021-11-09 | 2024-09-18 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| US20250161447A1 (en) * | 2022-03-03 | 2025-05-22 | Board Of Regents, The University Of Texas System | Anti-cd19 and anti-cd79b chimeric antigen receptors and methods of use thereof |
| CN116836283B (zh) * | 2022-05-17 | 2024-05-07 | 苏州万灏生物科技有限公司 | 具有多种免疫调节因子的增强型溶瘤病毒及其制备方法和应用 |
| WO2024243578A1 (en) | 2023-05-25 | 2024-11-28 | Dispatch Biotherapeutics, Inc. | Synthetic cancer antigens as targets for treating cancers |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0170269A3 (en) | 1984-08-02 | 1987-09-23 | Kao Corporation | Medicated cosmetic compositions |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| FI951138L (fi) | 1993-07-13 | 1995-04-13 | Rhone Poulenc Rorer Sa | Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US5677170A (en) | 1994-03-02 | 1997-10-14 | The Johns Hopkins University | In vitro transposition of artificial transposons |
| FR2730504B1 (fr) * | 1995-02-13 | 1997-03-28 | Rhone Poulenc Rorer Sa | Procede de preparation de genomes d'adenovirus recombinants |
| DE19648650C2 (de) | 1996-01-29 | 1998-07-02 | Schering Ag | Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung |
| US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| CN1242051A (zh) | 1996-12-31 | 2000-01-19 | 昂尼克斯药物公司 | 用于肿瘤治疗和预防的致细胞病变病毒 |
| US6420524B1 (en) | 1997-02-20 | 2002-07-16 | Johns Hopkins University School Of Medicine | Gain of function mutations in ATP-dependent transposition proteins |
| IL135507A0 (en) | 1997-10-09 | 2001-05-20 | Pro Virus Inc | Treatment of neoplasms with viruses |
| US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US6291214B1 (en) | 1998-05-11 | 2001-09-18 | Glaxo Wellcome Inc. | System for generating recombinant viruses |
| US20020019051A1 (en) | 1998-05-27 | 2002-02-14 | Monika Lusky | Chimeric adenoviral vectors |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| CN1110553C (zh) | 1998-07-15 | 2003-06-04 | 杭州赛狮生物技术开发有限公司 | 基因工程腺病毒及其用途 |
| CN1257286C (zh) * | 1998-08-27 | 2006-05-24 | 森泰莱昂公司 | 用于递送异源基因的定向腺病毒载体 |
| AU767975B2 (en) | 1998-09-11 | 2003-11-27 | Genvec, Inc. | Alternatively targeted adenovirus |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| CA2678259C (en) | 1998-12-09 | 2016-10-18 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| ATE332364T1 (de) | 1999-02-22 | 2006-07-15 | Transgene Sa | Verfahren zur gewinnung von purifizierter virenzuammensetzung |
| CA2364562A1 (fr) | 1999-04-09 | 2000-10-19 | Aventis Pharma S.A. | Composition destinee a la conservation d'adenovirus recombinants infectieux |
| DK1681353T3 (da) | 1999-05-17 | 2010-01-04 | Crucell Holland Bv | Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35 |
| WO2000073478A2 (en) | 1999-06-01 | 2000-12-07 | University Of Washington | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| WO2001011034A2 (en) | 1999-08-09 | 2001-02-15 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
| US7396679B2 (en) | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| US7223593B2 (en) | 2000-01-21 | 2007-05-29 | Biovex Limited | Herpes virus strains for gene therapy |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| JP2003534806A (ja) | 2000-05-31 | 2003-11-25 | ジェンベク、インコーポレイティッド | アデノウイルスベクターのターゲティングの方法および組成物 |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| WO2001094413A2 (en) | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| ATE449859T1 (de) | 2001-01-04 | 2009-12-15 | Goeran Wadell | Virusvektor zur gentherapie |
| US20050175589A1 (en) | 2001-07-13 | 2005-08-11 | Btg International Limited | Anti-neoplastic viral agents |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| CA2474777A1 (en) | 2002-02-01 | 2003-08-07 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with pods |
| US20060147420A1 (en) * | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| WO2003092594A2 (en) | 2002-04-30 | 2003-11-13 | Duke University | Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use |
| JP4603894B2 (ja) | 2002-12-03 | 2010-12-22 | ユセベ ファルマ ソシエテ アノニム | 抗体産生細胞を同定するためのアッセイ |
| US20040167088A1 (en) | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
| US20040213764A1 (en) | 2003-03-28 | 2004-10-28 | William Wold | Adenovirus replication-competent vectors expressing trail |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| DK1644412T4 (en) | 2003-07-01 | 2018-11-12 | Ucb Biopharma Sprl | MODIFIED ANTIBODY-FAB FRAGMENTS |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| CN1934253A (zh) | 2003-07-18 | 2007-03-21 | 昂尼克斯药物公司 | 用于治疗疾病的b亚组腺病毒载体 |
| US20050186178A1 (en) | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| WO2005107474A2 (en) * | 2004-04-30 | 2005-11-17 | Introgen Therapeutics, Inc. | Oncolytic adenovirus armed with therapeutic genes |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| CA2567094C (en) * | 2004-05-26 | 2014-11-25 | Schering Aktiengesellschaft | Chimeric adenoviruses for use in cancer treatment |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| US20060292682A1 (en) | 2004-07-22 | 2006-12-28 | Hawkins Lynda K | Addition of transgenes into adenoviral vectors |
| CA2589602A1 (en) | 2004-09-01 | 2006-04-13 | Genvec, Inc. | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| US20060205080A1 (en) | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
| CA2620495A1 (en) | 2005-08-31 | 2007-03-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| CN1961961B (zh) | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| DE102005055128B4 (de) | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
| ES2304281B1 (es) | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| US8216819B2 (en) | 2006-12-22 | 2012-07-10 | Psioxus Therapeutics Limited | Generation of oncolytic adenoviruses and uses thereof |
| CA2700714C (en) | 2007-09-26 | 2018-09-11 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| US20110034560A1 (en) | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| CA2723580A1 (en) | 2008-05-27 | 2009-12-03 | Oncolytics Biotech Inc. | Modulating interstitial pressure and oncolytic viral delivery and distribution |
| CA2737241C (en) | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| AU2009299791B2 (en) | 2008-10-01 | 2016-02-25 | Amgen Research (Munich) Gmbh | Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody |
| ES2385251B1 (es) * | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| WO2011043719A1 (en) | 2009-10-05 | 2011-04-14 | Ya-Fang Mei | Replicating viral vectors for gene therapy |
| KR101957616B1 (ko) | 2010-08-16 | 2019-03-12 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 아데노바이러스 조립 방법 |
| WO2012038606A1 (en) | 2010-09-24 | 2012-03-29 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| PE20141521A1 (es) | 2011-08-23 | 2014-10-25 | Roche Glycart Ag | Moleculas biespecificas de union a antigeno activadoras de celulas t |
| WO2013074507A2 (en) | 2011-11-14 | 2013-05-23 | Regenerative Sciences, Llc | Suspended particle delivery systems and methods |
| CN102586327B (zh) | 2012-01-18 | 2013-09-11 | 陕西师范大学 | 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用 |
| NZ701324A (en) | 2012-05-04 | 2016-09-30 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| WO2014138314A1 (en) | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Oncolytic virus |
| WO2015040234A1 (en) | 2013-09-23 | 2015-03-26 | Crucell Holland B.V. | Adenovirus formulations |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| GB201318793D0 (en) | 2013-10-24 | 2013-12-11 | Plaquetec Ltd | Vascular Biomarkers |
| LT3021859T (lt) | 2013-10-25 | 2018-06-11 | Psioxus Therapeutics Limited | Onkolitiniai adenovirusai su heterologiniais genais |
| CN106029889A (zh) | 2013-11-22 | 2016-10-12 | 德那翠丝有限公司 | 表达免疫细胞刺激受体激动剂的腺病毒 |
| CN112759650B (zh) | 2014-04-03 | 2024-10-01 | Igm生物科学股份有限公司 | 修饰的j链 |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| JP2017529070A (ja) | 2014-08-27 | 2017-10-05 | サイオクサス セラピューティクス リミテッド | アデノウイルスの製造方法 |
| GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| KR102626276B1 (ko) | 2015-03-17 | 2024-01-17 | 틸트 바이오세러퓨틱스 오이 | 이-특이적인 항체를 암호화하는 종양붕괴성 아데노바이러스 및 이와 관련된 방법 및 용도 |
| HRP20200439T1 (hr) | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| MY193281A (en) | 2015-12-17 | 2022-09-30 | Psioxus Therapeutics Ltd | Group b adenovirus encoding an anti-tcr-complex antibody or fragment |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| KR102427563B1 (ko) | 2016-08-29 | 2022-08-03 | 싸이오서스 테라퓨틱스 엘티디. | 이중특이성 T 세포 활성화제(Bispecific T cell activator)가 보강된 아데노바이러스 |
| AU2017345764A1 (en) | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| WO2018083259A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
-
2014
- 2014-10-24 LT LTEP14799117.8T patent/LT3021859T/lt unknown
- 2014-10-24 NO NO14799117A patent/NO3021859T3/no unknown
- 2014-10-24 WO PCT/EP2014/072919 patent/WO2015059303A1/en not_active Ceased
- 2014-10-24 SG SG10201804030WA patent/SG10201804030WA/en unknown
- 2014-10-24 MY MYPI2016000623A patent/MY175614A/en unknown
- 2014-10-24 HU HUE14799117A patent/HUE035875T2/hu unknown
- 2014-10-24 EA EA201690545A patent/EA036414B1/ru unknown
- 2014-10-24 KR KR1020167013117A patent/KR102272932B1/ko active Active
- 2014-10-24 US US15/031,716 patent/US9987314B2/en active Active
- 2014-10-24 HR HRP20180317TT patent/HRP20180317T1/hr unknown
- 2014-10-24 DK DK14799117.8T patent/DK3021859T3/en active
- 2014-10-24 PE PE2016000536A patent/PE20160951A1/es unknown
- 2014-10-24 SM SM20180130T patent/SMT201800130T1/it unknown
- 2014-10-24 TR TR2018/02728T patent/TR201802728T4/tr unknown
- 2014-10-24 PL PL14799117T patent/PL3021859T3/pl unknown
- 2014-10-24 CN CN201480062880.3A patent/CN108064159B/zh active Active
- 2014-10-24 RS RS20180246A patent/RS57043B1/sr unknown
- 2014-10-24 SI SI201430609T patent/SI3021859T1/en unknown
- 2014-10-24 CN CN202111375653.4A patent/CN114457044A/zh active Pending
- 2014-10-24 SG SG11201602887QA patent/SG11201602887QA/en unknown
- 2014-10-24 PT PT147991178T patent/PT3021859T/pt unknown
- 2014-10-24 NZ NZ718931A patent/NZ718931A/en not_active IP Right Cessation
- 2014-10-24 CA CA2927968A patent/CA2927968C/en active Active
- 2014-10-24 EP EP17194455.6A patent/EP3372236A1/en active Pending
- 2014-10-24 EP EP14799117.8A patent/EP3021859B1/en active Active
- 2014-10-24 ES ES14799117T patent/ES2661132T3/es active Active
- 2014-10-24 CA CA3183645A patent/CA3183645A1/en active Pending
- 2014-10-24 AU AU2014338864A patent/AU2014338864C1/en active Active
- 2014-10-24 MX MX2016005170A patent/MX373835B/es active IP Right Grant
- 2014-10-24 EP EP20210597.9A patent/EP3831398A1/en active Pending
-
2016
- 2016-04-06 IL IL244944A patent/IL244944B/en active IP Right Grant
- 2016-04-21 CL CL2016000959A patent/CL2016000959A1/es unknown
- 2016-04-24 SA SA516371011A patent/SA516371011B1/ar unknown
- 2016-04-25 PH PH12016500759A patent/PH12016500759B1/en unknown
- 2016-05-25 ZA ZA2016/03646A patent/ZA201603646B/en unknown
-
2018
- 2018-02-26 CY CY20181100227T patent/CY1119955T1/el unknown
- 2018-04-30 US US15/967,093 patent/US11439678B2/en active Active
-
2019
- 2019-09-12 IL IL269304A patent/IL269304B/en active IP Right Grant
-
2020
- 2020-12-23 US US17/247,787 patent/US11938159B2/en active Active
-
2024
- 2024-02-21 US US18/583,342 patent/US20240325472A1/en active Pending